A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
A RANDOMIZED PHASE 2 STUDY OF PF-05212384 PLUS IRINOTECAN VERSUS CETUXIMAB PLUS IRINOTECAN IN PATIENTS WITH KRAS AND NRAS WILD TYPE METASTATIC COLORECTAL CANCER
Sponsor: Pfizer
Terminated
Enrollment to the study was terminated on 11Nvo2014 due to slow recruitment. There were no safety or efficacy issues that contributed to this decision.
Other terminated trials from Pfizer
Other Metastatic Colorectal Cancer trials with similar outcome
This PHASE2 trial investigates Metastatic Colorectal Cancer and is currently terminated or withdrawn. Pfizer leads this study, which shows 14 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 9 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2019 — Nov 2020 [monthly]
Terminated PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Jul 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jun 2017 — Jul 2017 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .